SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to Decembe...

Full description

Bibliographic Details
Main Authors: José Luis Piñana, Lucia López-Corral, Rodrigo Martino, Lourdes Vazquez, Ariadna Pérez, Gabriel Martin-Martin, Beatriz Gago, Gabriela Sanz-Linares, Andrés Sanchez-Salinas, Lucia Villalon, Venancio Conesa-Garcia, María T. Olave, Magdalena Corona, Sara Marcos-Corrales, Mar Tormo, José Ángel Hernández-Rivas, Juan Montoro, Alicia Rodriguez-Fernandez, Irene Risco-Gálvez, Pablo Rodríguez-Belenguer, Juan Carlos Hernandez-Boluda, Irene García-Cadenas, Montserrat Ruiz-García, Juan Luis Muñoz-Bellido, Carlos Solano, Ángel Cedillo, Anna Sureda, David Navarro, the Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Journal of Hematology & Oncology
Subjects:
SARS-CoV-2 vaccines
Breakthrough SARS-CoV-2 infection
Correlates of protection
Hematological malignancies
Allogeneic stem cell transplantation
Autologous stem cell transplantation
Online Access:https://doi.org/10.1186/s13045-022-01275-7

Internet

https://doi.org/10.1186/s13045-022-01275-7

Similar Items